0001193125-23-198589.txt : 20230731 0001193125-23-198589.hdr.sgml : 20230731 20230731081252 ACCESSION NUMBER: 0001193125-23-198589 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230731 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230731 DATE AS OF CHANGE: 20230731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 231125136 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 8-K 1 d518650d8k.htm 8-K 8-K
false 0001701108 0001701108 2023-07-31 2023-07-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2023

 

 

SPERO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38266   46-4590683

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

675 Massachusetts Avenue, 14th Floor

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (857) 242-1600

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   SPRO   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01.

Regulation FD Disclosure.

A copy of the press release issued by Spero Therapeutics, Inc. (the “Company”) on July 31, 2023 entitled “Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr” is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 8.01.

Other Events.

The Company is providing the clinical and business updates below regarding tebipenem HBr and SPR720.

Special Protocol Assessment Agreement with FDA for Pivotal Phase 3 PIVOT-PO Clinical Trial of Tebipenem HBr; Company to Receive $30.0 Million Development Milestone Payment from GSK

On July 31, 2023, the Company announced it received written agreement from the U.S. Food and Drug Administration (“FDA”), under a Special Protocol Assessment (“SPA”), on the design and size of PIVOT-PO, a pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP).

PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr vs. IV imipenem cilastatin, in hospitalized adult patients with cUTI/AP. The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The primary analysis for the trial will be an assessment of non-inferiority (NI) in the microbiological intention-to-treat population, based on a 10% NI margin, which is consistent with FDA guidance for non-inferiority studies in cUTI/AP. The FDA has indicated that positive and persuasive results from PIVOT-PO, along with previously completed studies, could be sufficient to support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.

Under the terms of its previously announced exclusive license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”), the Company will be entitled to invoice and receive a $30.0 million development milestone payment. In addition, the Company is also eligible to receive the following milestone/royalty payments under the terms of the License Agreement conditional upon achievement of a certain progression of milestones: (1) up to an additional $120 million in development milestones as the Phase 3 clinical trial progresses; (2) up to $150 million in potential commercial milestones based on first commercial sales; (3) up to $225 million in potential sales-based milestones; and (4) low-single digit to low-double digit (if sales exceed $1.0 billion) tiered royalties on net product sales of tebipenem HBr in all territories, except Japan and certain other Asian countries.

SPR720

The Phase 2 clinical trial of SPR720, a potential novel first-line oral therapy for nontuberculous mycobacterial (NTM) infections, continues to enroll participants with more than 23 active sites. Based on this current pace of enrollment, the Company is updating its guidance with respect to the timing of top line data for the Phase 2 clinical trial, with an estimate of such data being available during the second half of 2024.

Forward Looking Statements

This Current Report on Form 8-K may contain forward-looking statements. These statements include, but are not limited to, statements about the design, initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether tebipenem HBr will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether the Company will satisfy all of the pre-conditions to receipt of the milestone payments under its various license and collaboration agreements; the lengthy, expensive, and uncertain process of clinical drug development for SPR720 and SPR206, including potential future challenges with patient enrollment, clinical trial design and manufacturing challenges; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; the Company’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the Company’s need for additional funding; the ability to commercialize the Company’s product candidates, if approved; the Company’s ability to retain key personnel; the Company’s dependence on raising capital and whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that the Company periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

99.1    Press Release, dated July 31, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

In accordance with General Instruction B.2 on Form 8-K, except as set forth under Item 8.01, the information set forth in Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 31, 2023   SPERO THERAPEUTICS, INC.
    By:  

/s/ Tamara Joseph

      Tamara Joseph
      Chief Legal Officer
 EX-99.1 2 d518650dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023

Spero to receive $30 million development milestone payment from GSK

CAMBRIDGE, Mass., July 31, 2023 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in areas of high unmet need involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design and size of PIVOT-PO, a pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP).

“PIVOT-PO was designed in collaboration with GSK to provide tebipenem HBr with a clinical path to becoming the first oral carbapenem antibiotic for treatment of cUTI, if approved,” said Dr. Kamal Hamed, Chief Medical Officer of Spero. “With increasing prevalence of antibiotic-resistant bacteria, cUTI patients often have no choice but to receive an intravenous (IV) carbapenem antibiotic in a hospital setting. The goal of our tebipenem HBr program is to provide appropriate patients with an efficacious oral option for the treatment of cUTI. We believe that tebipenem HBr has the potential to deliver strong value to the healthcare system.”

PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr vs. IV imipenem cilastatin, in hospitalized adult patients with cUTI/AP. The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The primary analysis for the trial will be an assessment of non-inferiority (NI) in the microbiological intention-to-treat population, based on a 10% NI margin, which is consistent with FDA guidance for non-inferiority studies in cUTI/AP. The FDA has indicated that positive and persuasive results from PIVOT-PO, along with previously completed studies, could be sufficient to support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.

Spero is also eligible to receive the following milestone/royalty payments under the terms of its license agreement with GSK, conditional upon achievement of certain progression of milestones: (1) up to an additional $120 million in development milestones as the Phase 3 clinical trial progresses; (2) up to $150 million in potential commercial milestones based on first commercial sales; (3) up to $225 million in potential sales-based milestones; and (4) low-single digit to low- double digit (if sales exceed $1 billion) tiered royalties on net product sales of tebipenem HBr in all territories, except Japan and certain other Asian countries.

About Tebipenem HBr

Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is Spero’s novel late-stage development asset, an oral formulation tablet of tebipenem pivoxil, a carbapenem antibiotic of the ß-lactam class. Tebipenem pivoxil is marketed by Meiji Seika Pharma Co. Ltd. (Meiji) in Japan as an oral granule formulation, Orapenem®, since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis. Carbapenems are an important subclass of antibiotics in the treatment of drug-resistant Gram-negative bacterial infections. Tebipenem HBr is being developed for the treatment of complicated urinary tract infections, including AP, caused by certain microorganisms. If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.

Tebipenem HBr Research Support

Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

 

  •  

Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

 

  •  

Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

 

  •  

Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, as well as the regulatory path forward for tebipenem HBr and potential FDA approval, the potential commercialization of tebipenem HBr and its future value, the potential receipt of milestone payments, and royalties on future sales under the license agreement. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether tebipenem HBr, SPR720 and SPR206 will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and

clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero’s need for additional funding; the ability to commercialize Spero’s product candidates, if approved; Spero’s ability to retain key personnel; Spero’s ongoing leadership transitions; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Ted Jenkins

Vice President, Investor Relations and Strategic Finance

IR@sperotherapeutics.com

(617) 798-4039

Media Inquiries:

Lora Grassilli, Health Media Relations

Zeno Group

lora.grassilli@zenogroup.com

646-932-3735

EX-101.SCH 3 spro-20230731.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 spro-20230731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 spro-20230731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 31, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001701108
Document Type 8-K
Document Period End Date Jul. 31, 2023
Entity Registrant Name SPERO THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38266
Entity Tax Identification Number 46-4590683
Entity Address, Address Line One 675 Massachusetts Avenue
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (857)
Local Phone Number 242-1600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SPRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d518650d8k_htm.xml IDEA: XBRL DOCUMENT 0001701108 2023-07-31 2023-07-31 false 0001701108 8-K 2023-07-31 SPERO THERAPEUTICS, INC. DE 001-38266 46-4590683 675 Massachusetts Avenue 14th Floor Cambridge MA 02139 (857) 242-1600 false false false false Common Stock, $0.001 par value SPRO NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d518650d8k.htm d518650dex991.htm spro-20230731.xsd spro-20230731_lab.xml spro-20230731_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d518650d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d518650d8k.htm" ] }, "labelLink": { "local": [ "spro-20230731_lab.xml" ] }, "presentationLink": { "local": [ "spro-20230731_pre.xml" ] }, "schema": { "local": [ "spro-20230731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "spro", "nsuri": "http://imetrix.edgar-online.com/20230731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d518650d8k.htm", "contextRef": "duration_2023-07-31_to_2023-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d518650d8k.htm", "contextRef": "duration_2023-07-31_to_2023-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-198589-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-198589-xbrl.zip M4$L#!!0 ( )I!_U9?]0;CSQ@ /J& . 9#4Q.#8U,&0X:RYH=&WM M76ESXS;2_KY5^0\H)[,E5^GV+7N\Y?$Q<3)CNVS/;NK]DH)(2$*&(K@ :5O[ MZ]_N!DB1$F59MGPD\50EED@0:#3Z>+K1H/;^=3<,V(W01JKPXTJKWEQA(O24 M+\/^QY4D[M6V5]B_]G_XQ]X@AH;0.#0=7\B/*X,XCCJ-QEU7!W4CO'I?W33@ M1J/=;+=77,/$U.)1)$S6NL=-MZYTOY'>*30/51@FPZSQ[>UMG;K'!_Q8-_") M!C2J02NAI9<^=Q?(\'OAL=LU>JBUL[/3H+MITZF6V0#M9G.M@;>[W(BTN8FT MRIK+H8BUO*L+O\]U38706-0]-<0YK#6WUEH9/4:640,CM!J_??URY0W$D-=D M:&(>>ME82:QG4K;3@+MI0VG4>KNU=<\T7(OL@;M9;5O0EN;QVZ?++^/F<7G[ M<=-&K'EH>DH/>0R"@SUMU)KM6GLSUTD-Q*+042HF\_K9KN5X"8/+^Z8ZP46\ MZT^(IVN\V; W7=/9 H.BOD(R+[B/?V,9!V)_N_;K7L-^A&L@#)QA#S7QWT3> M?%PY5&$LPKAV#5*ZPCS[[>-*+.[B!O7(&OA_QRKW;66_QP,C]AJ%SJ<&D_['E9^)CM]A MQ-^/0^#(Z!"&U#PX#7UQ]ZL8K>1(FM%@0=*:H#M;S5:KN3U-7V.",UKTA 8C M)@Q\1XWN&-(X&(N1,>B@(?FX8N0P"E!PZ-I (RFH\+54G^MWQD]O<^UIA4OT M8-OQ#%9I?Z]1G(^;?6'&]-VH1-NOI$ =QVY:O0>P.WU,T.)E7Z6/%WI2:$8D MB%+U/CS]M;A@DP\CU:7]1["BRL^^@F;K^(C'8G],6_KD^-Z85G]&V_1.-FPV M3J/ G8R;8^XU\AK8 $V%/SE]Q:=J/)#]L./!7(1>*=Z_E7X\Z&S7-V2XFVL; MB%Z\.^2Z+\,:?NXPGL0JO:)E?^ N87=1VAD:S=I T%UPU%'61:RB3NYK5\6Q M&M*5KM) >GJE%=TQHP+ILQ^;]&]E_Y\_MC:;NWN-:-9 :_,':C]ZH%RWZ] ) MFYX Z\'2U(S\G^BTMK/O/3Z4P:AS#1[9L#-QRR[5D(>[=._6TMU5@;];LCS? MSDZOCX_8U?7!]?'5;'*:+T3.U?'AM\O3Z]/C*W9P=L2.?SO\^>#L\S$[//_Z M]?3JZO3\[$DTMI=!XW^X&0 1I5* MYN:C)+/>A&9%X=RU6MIN?9B>_0.U=#R9U$B4+9A=CA>0JI/SRZ]LST0\S S1 M0,:B!E<\ <[S5O,(G,DL%'&DO 1!1 [)/-Q3$THJNNB]!I*R_RXQSR(Q2]%Q ML$*7QV?7[/+XXOSR^O5MSD6B3<+#F,6*70D/9A#](SJ6(E(Y9)?TN., ? M86(F;J ETW1;^*N=V2%&:APN"$,=6VBUJ)5@-N3[N )A8L>'#H;P^,#GHQ%0 M),*5_5^28&07?*U59?CDM%%YMR;+MR;M]66(VVSIL='@I>A+@Z%_? 9W%G8Q M5Q?'E^?L^N?CRX.+XV_7IX=7579Z=E@O"0V?8"&:R^!$Y?B.@R5 !J"^Z6SB MC!MF(N%A0.0S&3(9&P:V ]1/3UJV=]F>(=M/80RF=7@W$,P308# B#*>S17Z M'G'?3[^[L=Q]0#\IS>6/3'8(_W.TZ[1)Q/NB MUM6"?\>4I_1%A]\HD) ',ZY%2U<A0^4]R@)@GQ7Q&+"*M;G!8](!'(N"WX QG M@NF'BD$J\U/MGX6'CPXZ+)-/9"#@7A=LT^(IPE9M;;N]N3F38W]EQEWSNU.7 M8/.(4X_DXOIF;7UCI[FY70*XIMCX'-J^O21E?ZS?7TH 7B'[@)&*B@="LS\@ M/C"^I#AF(5#2>@;B (?(O"U;M;[U==3B=9?I4 V'TIBWL"IH^9A5VK_Q@IS6 M+^M7=78\C (U$OK55Z5H4]F9JH\7AZP?_ ]1Y)\6E5*8\S18NM%<,IQMA>' YM8&^\J-X=X@,2*&&/7@1H3)%"JM MS@OYIXEI+TQ,:WW/)"5JMK7QH=R6Q0- *PFHU4F@E)Z305K(N+SD A["QW-] MK6[#A3EVR(==+?W^H]>+<,RYOH# 1%*5Q;+#G()PE:W0*_C!+(!^4KSH.'BA M8,[!_\GH,6'B?K/=6MNY+P1\RQ!\#O\JCD.8&(LTB)>,>,#$G?"26-Y@O@S\ MKC"K;SMPJ\#2,ES;U:EE*<$&"R;_EV)EQMG6?_ZXW6YM[1K@0R"B@0H%"PEQ M5C$B"!)$%XR#Y("8^F*VB4"+= #-'B72E>V-K=7I5.VCX]\O"A;L B?SR)"W MO=ZN@< TW[S1S1-P M,?/%A[:E:3U93P8HY]* T,&BP2X[V+[(+&] BOL ECV2X48*22/;>W]GJS;GM,M5)=?G@U5IZ>%7#B7:.$=HB)2BF869J/AI M\ /3G1WK_ EV1=YK=5XP=?B Q,6,V9;HSJON%E[CX4!;5^L-F!=P8UXJA?U8 M)KXVQS1'Y=WK:M;8OQH-H5W%O-C^]PLP[3EVR<]<-2E)F7 NYM6WRE7(0"&! MHK&W*#JM-[B/.R=LMQYPU&IW2;,7WWX#9 %LN8J5][W*?FJ"@+58Q#6[X<'T M'NJK;7#,FK]33JN6CZC2OCQ_\U-,ES@%:H^I1Y_"T*B2Z?XFG@\YX\;G_V6? M P7(&E!3 +B)?>7ZNXA+&?1B$.\T]!'V"M8=,8^R[=#C=U!C055K$REN:1C@ M5H#..&B?];6ZC0>(GB-,>W/#?-&3H:UFMUG'YD8*""=2CO9DS!JKX#)O[5+F M,6TLJ0X^PCIX+*![( 1O=VM9-FAZS+)C.?,[3:E#.#[5?X[,^M-.^,Q?I^-R MGEL=<9IR_V9TVL-GZN#0/O]BP>+ST=X]L?RKG3ZW MVY9N\_*'?X!K*15,,9R22[R4 RU= 2L/H"6XY2.S8L\:X2M#,H #0:?2G1]W MZ-]N.J'HKI!::C@B[M\87NXK!7[XQU3R[-/YY='Q9>WP_,N7@XNKXT[ZX6TG MSUJMTNP9HX\@2--IH>GRC=-8#*UT;-6;K7I)K4F^M]=*=MV'O^TT+T4_">SF M],D1.Y+&"Y1)M*BS13)'FS/L,0T'AA3DL;/S84'[? #V,5*N[E[F#H^^-;:!7L8LNF3 MHHS>*A) M^ZIZ:[901B"%?: T"L\A =V^4(K@.DJ8 ?& (68(&0'?2TH56CM M^LG1 9G[BP&2OC8?0%R<_OO\NG9QG@*':]KLPE/#HBLC$8HA^_F3=K-!?-5+ M="C- $CG"%H&LBMCMK-3;Z$_(,QQF&B-!+F3O+C<#ZU_2(5[\EAD;C$7]@_O MAF3:D&S_J0W).4'_8SP/;MZ \<#XR6D]*H@%2@B>T"IX@!60>X"XP(8D!I # MV)8DPA/EQE4) < #B$5/Y)6.'H$0=:O=K-]S3MB^CV/)3"^3)?KQ M\R.,DKQ1,3[R6.-TF#*SW$KM9LN ^R+"$UBB^1,$;DWV508!.IXC<0,LCX@V MN"9,C!6&%WQ$5WI:#=GGJU]9>5W=9FKJ)(8I1/CSBE !(OO0J I^NS6 MU=CPC.\T$WSP&YY5.5$0!: T'>FDSP[\(; 1(PKRQ17G@F"54J=536O%[G4] MZ8-7%[D'H4,GJX7Z4B^!8"P:@:B$(AI@A&Y8 MY>!B]5X]G!4I/DDF%M813(&P/N5QJ@Q"05\-82B_RGR5@&&L=8&%\&T^9Y7& M;P7VWH"Y/?TWDT-WS9,!QW)Y&2+WV$"9B,S#_Q =^$D03ZX&,+IQ<%&G5Y)$ M6@YQ.0364',//H1^I"09C2 T\@4N!X(W4'.3:1"(+."RZD@N"6!RDCV $2R M*$@,&TI/JZZ$L*9/=P2F!^VNZ2KC,8GF_#+>>0W <%TZ,K9Z2JN @XQR8>G MSYGJ4)&/(.NU&$!+/#'S2$4.W5<9O@G01U/ 6:OY@9V=.K6HNO0[)J9@03$% MG_<1_43Z^*),XM1CV6!BT&&!A;-%<<,!,'V2YEI\8!1(!(D3^@DT50#"3<(- M?@69 _DUUI ^PG2!Y7"IE@@3++9BEZR1P+$=E56XE 0^RH%)4 ]06:C4-XD( M/%-9\4V9J>.HY[00UN!CC@?FFS=C10-6I3:06!<'ZQ^/0)%4G:VMLB^.4:F? V P]G-YIYRJ99>2H]]%\&!D1PKQO'=)=#^+48_%):]4IQPG-,XZ8)<)X%"(#7R $%ZKO:Y-8X@FY#.\-E49C!)QLKX'%(#^+Z U6]%.J5':; MRJ6,4$RI;(!Z1+6?,GH4.M/A&!@E0PPT'.)$W+>D1!0,#/8;S\2 0*J(T;3A M49[AL'(65M,-$@::*8?N+70F =A"3W<%10@W'+ OFET?PPH;ZQN!9A)01M## M9R!Z6Z^G2?=<3I^2VW_?Q/Z+G4>?K\4G2M]R[;,O2GW'1:2CQ-8SOI9F/RU_ MFMKS(1^1BJ))[=E)U@(W29--DH"Q$;DK#CP*@/!)C,PW5'[H3 M7'L#NI#'"C0H'QK"3T8-!?- URT$GL$,:!$BB,O> 4XI?PN+2/L!=#@@"-RM MIAEQ=PDAX.0U,T!L/WE5W*&-FKP:!3R&5CV:!M\FH, M0BNF*=#JCQ+":/L=HI:2(;L /8'G4Q-T9G-Z (&O%YJZG#JI]#I8Y]S8Z&1R M=U!J0H%''.GT-7XW&7A-7V5D0/0"K@%E1 Z)@B <6)2?2B!JB"^Q'CT[X@,1 MATN;J7%H9,6 !. >V:%@S':-5-UPC2$,DT/48-PK[X'W4]KDH[.LA*6 EBB6 MX/X->;5XH%72'Q03R1G(]>A@.@;9P' !U .FQ# /H[P8,18)%S MA?@X/:V,L8 S_W,]6D3'(5SD:5+GE@:Z49QV-!4WIY$M.HE4&;/, 4HU5MMW MW1!;F>>RW$>/DQMYYW0BCL+DYP M.SGMYF8A/Y/A\UX28P[3 ^B(@PN'GUWVM "')^Q +M$."")!.V,!Z;BO\:)D MVMK%6=@RN(?ZW#3)D::,;MS;8J=[3"=3[&"WU.-KT!$K7!0) !:C*,+&%>,) MP0(XSE;=^J4BC)L+-FUD@U"025_2YAIIN[,%?OGH(0:Y9)/&ZMP#R0'^V0\NI?G.3FRCU.<;08H$RH"216\Y,-92YBV,)0.E M#>S_D']/%2C; ,\=?<-L&/![9GQN+:VZJN"'JWE9MQ0"E M+ ,;>PK+\9OQH !?04=I>'//0-:"$]!4%>0L<+$.>4_S7CQTOC_OO5#&FB2 M.;:Z/,72E_6]>.99BV=V_M3%,R=9F6\NVV%M(M5R/:2B9HEGHO^< E5^)KHH M3_3S'V]+.J:$X5%K_OR'8Y>BH]U,29_=%"?Z.UO;G1],7=SDZK/HB' M=-8=(JA+6V5;)2_HE]0_H6CRF4?T&/HLPBQD@CH-;%.;-77IWI[(725 ME7:XO4O\<90L-K'9!H0(#$MK;89)AMFOQA;#&&J'M?PVD1TNO8PZ5POF0JNL M:CN-JZ@R#U,$*;CU,05"I0O=+""#>&O\!(9\4:(C9>PN;_'LS_8#C[15*5RL-(>,_B@1W"J@[6*N!TEC*.55^\9> @J7@;P+E;Z38;1$X>/][XQ?J M\;YWI"R?M(TW@%3=O,=X;,W^,F"G!!DNX:3^ T:?_4MNCT>DJ#;W05*Z/XU) MGZOM*V'=>V1\.>OX##T36/XTZCP?S8N](&7.L>(%_5/#--@UAV$X^P5@7C1X M\;>C_ 5$Y/E[GEBB]^5Y6ST?#J3HL2^B#Q'G.?U @"Z-B4LB@KU&5_DCN#*( MA\'^_P-02P,$% @ FD'_5MTHZY*$$0 )SH !$ !D-3$X-C4P9&5X M.3DQ+FAT;>U;:W/;1K+]SBK^AREMDI*J2.KEEQYF+27*%K.RI4BR<[/?AL"0 MG#6 03" 9/K7[^F> 0B0M.3-1KZWZB:52@G@8+JGGZ>[)\?GM^\N^L?G9X-A MO]TZOAW=7ISUS_ZG>W#0VSW>=H]XO^T7B..3R^%OXN3MZ>7%Y?7KC5_/1[=G M&^+F]K>+L]<;D4Y4=Z;T=)8?OC=9+*.-OFBW\/VI2G*5]8^'HX_EXGL=YK/# M5[WG.MD0,M+3!!NH2;[!9*[*9;',ICKIYB8]W$GS(^&?QR;/3>Q>34R2=ZW^ MH@YW%\\3&>MH?GBK8V7%>W4OKDTL06EP,7K[_O5&1DQN](]/^F>?9WJL!B<3 6F5MC,_%8)HIQ7_=ZWPFW@P'()V)JYFT2NR+XS>7[V\K><]T MKKHVE8$Z3,P]2&WTKT8?+V^[5Y?'V[02I[[-B)29B%LUUJE*5"S.3[)*+.OU M\B12&?7_Z"E$SH?05JC/D%VN0I$;,59@SXM)9S875S+7(-9QC^W61VUA!5CS M[!>QM[,'NMNC!PZ]N_.=LKE)E$CEG-],,A.+MS?_J-A_0E/NGP[>G5R/AF_/.N*=M+;7$3\7T5SL M[W:<"'_ZV^[SW2.Q:M\=,4J"GMA\+VTH?S\4-U?7EUL=(45<1+GN8B^5BP#Q M1 E$9I!1!E$NI"@V@P^W(["NDR J0M9N M4.2JW4KG4'>BTAEDB "P.;C:ZHFGC5S]1Z4$+WCV\F@Y2MW#UIS,V<)P[BB2 M8^/UR*(@-T8D2#-S![->$AROD.U6)6"(<>8B'43(U@VM3CC685=XB\S&TGT/ M&T7.,_ BSA>5&Y!Z2+20[$3(E BKL$/\OSH25FJRN9Z+1O^02._B7,98($YG M6DW$.Q4R(Y>3B0Y@?=B,/;\GG 1^)8ZA,G(SXB_-U)V,%'R!EBYXZBX!V,8?=QRO*^7!$4 M,3,VU62_"$ YF.Q1V!)3XTS7%-F2%B"B:29CRC8U3;'H4O"=JR7K!D^*Q",# M33RQ8DS**F=-@-B*-GKB5YQ-11K!K-WB>-%D J[&7Z8FI^!'SF9@6Q&$D F$ M!@-A0]*%HO>T<*9DE,\""F9V;G,5][R._[==9=E)(%8III$9RPA!+4-P@FE_ M(9,+33&.5'<,Z\?3XU&')=T4VYWM">!1'?MW@8XDS YJI\A2F0+1$S)$G%^. M5-#-]N#*F0BT'5.H\MK%'TF8&LW0+(J@/@%? @\1I8D4F4 ABB'4&: .MO^* MY:" 6M*H@)7'.L@,S#,R4_X)&Y"+D;EL"3(#$'Y4IH\NR $ANF;2)<)>\*7\ M[P@4-0\H$QG-X9\U>R41EZ>$@(V12\@/4[6BFA[+A&H31&%[19,P1;D M"^0P%'=LD:8FRWU:60<%)#G[(OJ1S'PRJM)\,[]W>(T4$5R8X0*%ZB=BL<7F-W4EG, M*%3C-8"0HE AFX4>@ $)&D>E@T*614K&&2[8;7G#[M[2Y6'_DKQ885+0.W65^)OR8*R1V)SKT'SA]WG MJU06B6R!V.OD*G]T\*:VR )0$)'])I&]O><3IZE:*ZZX[A M]Y^Z8P6/5HMH>'O^ M>F-W9^?'JJH^/7M_>W;]?ZX%11V?P=@ JZYOLCQEP=ZDN+DP"P)0GW4D9O,0 MB18I C"6]LK@6(CSJ,\/#IYM4;#CJ$=P\<61!?9&.!!(D\H7Z?7XP%4\%;P. M?-%F/J.*7,+"\X9EHGAS/% ;8#U"I^6(D#_9+]#543="<0#H'434>J@)LSP+ MF(6\/G%Z&L]1GNA_:7&C]"=).#&+I3A%;7*1AST4[/0CPPWO ;;B&_@^*2)5 MY[\C+C/'WO'-ATI9"TV\?/[CD0#%=3Z!55NH^HB445L$JJ&( ZJ;V/ZPI?L24%Y'X(XK61G MJ:7!95!,J9<**EN,65[-BLN6.*M1>U!3HU:+O46=TTW45#*Z6-?H(=2*, BJC95*@ IA4+3N MEP*6,='X:^1/B8IPZ)I+U+#A$+[YRVAXM<4Z?H/J1-Q"+)]\XT Z$QG/F7K9 M_5U;0_(&A!P?Z&B^^I."6_/#3=Y/[-RJ"0)>47@)I[AJ0 M*L2$8%?H>E"9QU83%2H.5_C-+EIO0T5+2I&>.@(-.H])BGB,Y_/SFTMDP[V=W5<[.SN[ST^_B^I=7N,4T6XU!AK?0^EK MVLPS)8&=*W_W&[5&]!B MT7_NK&U N_Q9:T.3 Z_O&R^BW]J6\[J/F&2C9;UB! L!DPJ6D,Z*0I# &.GR M)C0N')Q#\^NNP!F%X.KF[/#\H\'M;:LX@WAMGF]L;,A3L\N+JX& MP^'H_=OJ^>9J<%H^UT&?X^?:P4/Q6FS44*5&:1X"5=X9'?J%P_+CYS\N#G4[ M7/IQ'V#RHT>3E+]+9.E (H&@@W6?[2Y]MH9 ?:/F6E).XU-';6MF2RAOI=[.ZXN=Y;JNFC\!?(NS$N'U.-!Z8]4B$3)0%CO]?]:4.WPU5*6<#B6GO9T7G;H?$E:G MKFG9V"U?G@XZ[R9^/<-SA6 M;#)FCVY9N8X$CVH$,/CQJ'_\H3_+\]0>;F];TE5>4U4/&/1X^T/?W0\YZ5>= MO"@6%=DV6R2JC!@-5 M!F5[W.%U/ZNE8LW=V)II9TUT4)!85 M1;Y]CT^FU. RV=Q=)O!B<0FN.:JAV5+5/Z?.0]D+Z2Q-HNL5CW/KU;F/YWA2 MY#3ZY$GU\C;K Y6>&"7"HO)&;+'* MC92^8@L4?:AGY"L\[;*WF]?8@B1M_4T'&%=Y:\*]H.EH\XV=40NJ^<[=5VN^ M0_Q*FF^DCI=>@)M IQ05W?MVR_T0K))P8\_FNQS>I9;)9N9?*[R0NZB8(JIJ M_N O)RR=!F@J7ED*,P[URB%+/?NWL+<%19T4:O&>E%C%9]<0MM70#$IVTPH+ MSXID1C< _>@+GCP(\H)-R3D8E(1*9#+!:EPT?LQ@E.C6S@A^P#2Z2 MW-;$UIW,N)VWZ+Q.@.Y,UBCD[V>*N6VX0ZX#UY+,/6S!"!GP3(=W4Q-*=QQZ M4@.IT12J%A-"%=A)4^*2ML+2[ J5)*9*(KY?,=BZ8->9'Q#$ MV@V+>;A>MKBK1B@%>W(T]7NA^?H63^H5*:]F*Q!\$NAE!NA;ID8=+'(ZF*>O M/59S E]"L\9E I\9"5F!^&SLCTA6!&S'4)M188]/2S1H[ M+@XBZ83DR).B,0*/9)'@Y#X/^7F_NPSJIA+DSBK-I;]3UV38?X8#RG&D[4R% M"XJ5:8P)$'&KE(#"MT&.\NY/>??"1>8U6Y9I>6F#HR;2 433[@0D?IV%W)TG MXHA7BX"B*NR_VEM5K@Y8KAILXV+C$EF^ZLOM^IJYT!0 9G'$6I1C'>E\3FPT MB2T!M?^$:FW/3#$8_:3F?&_')(F*EE:;9&K(2H%A 6GL3*SZ&#MELD-9]SV=U27XLM;GNE=#TIM*6-5Z"S2@-\ M;<)?&O YCQI^06&MLP$>X7)VO];VDWCCUI273!6'$[XH*B::7-(Z3W-%IR-/ MMH/0$W6*L+WW*Z4 M#IFB9Y);0\QW6MTS#O!C:NZ,\M_+._3\8192\V=$\+4(6YQ$[QRL:()WKSWN M';&).Z)DD'S,GCA';KY3&9>[D;=,ACI^(F9$D3)G#)S:K8<@3>Z L;O&Z#7G M/+A#-]8IC.F)UP6I. (TM1QP#0+,U(_ZC0@--BHKJ0<(.DS,]=18<1B@>3!? M;;(+J7/Y^#7!$W$^7DV4_M)K71\I M@17\^V>50.CV@>/^*3CD(]W&OJ+A5,@H<,W1&=U68]$W.N&(_T KXL^Y>O.A M/[K^^U=[(D\ME\T7NR^WQ,N#5]UG._L'WZ7Q\HZOB(P2 D.:[OQ]!U.[,)FD M3AK";13I3CDM=ZQ4)D 0_TFE_4^5&+!ABO2I]0JSBG#FWK0\\]^_@/:42#=, MZTE-^[&NZXMG+[H'^WO=_9?[S^M]_O6E%LSDXZ=I,O:K90- MT9>Z/N<[YSL_W8/7BTK"%1HKM#J,LB2- %6A2Z'FAU%C8VX+(:+71T^?'/P3 MQW!\OKZZ2<"66U;!Q9L$FA*P9QW.N_N_@,7UKK.4Q0(K<( M%;<.#;QMA"SS43H:95GZ7_)J"#/(O3THN<,<]M@X8Z0XAE'^8B]/4_CX =X' M*PHN1(5#J*Z71LPO'3PKGD, '6NE4$I)A MEFA:-%=8)IW5A2US6UQBQ9\^ :!\*9LK,ME4AY%/1)>'Q=3(1)LY*YUA;EDC M(Z68M-"((AI ?XW;P% AO,2N@#-NIP'42WQZ1@.$K8U>:5.&G!&+!,LY-[%6 M4B@,E?+I2??&V0!8HECA C6+13+75XP$ZTZ\7-P=S"A-QXP:PU&^<0 AU]^W M(+QX2CTR=+(!N1X'0+:_O\^"=(U2Z6Y'T%E_R5IAT.:.,C)M')YH4QWCC#>2 M4(WZT7 I9@++H$4-6Z%RMW1N:SANYNC.>86VY@4^*.748'?%1Y0S]O7#V:?0 M>]&1!P"$=A15K8V#MBO/=!&&94M:_:^XKT;LK^)L%(^SA(Q%H#;8;RDEL$<3 MZ8O\("*K#MF9B+VOD_TA]H?[O-_=_P_.P/J ^_CW??S9JYWBWU@0?X")5N>/ M)3/8<@^OB>*B:)=8>]R]+C?(1_5FOQU\'EYN=;R^3CJOP2=72KO@:,B$U[50 M,]U=T:5OXKSOY G.(*RQG)O":(G;EQVCS5ZC<8*6_LTPM 8N#Z54V'-P>+R]F!$%Y=D.OQSKA//C,B\'+Z?7D MZZ+Q;U+__4:5[Q517)Y2AYDJT(M T(LR(?5O.ZFOR/9T2Z0_=2*T<9;Z#_WG MZRT,CUR5T)J#@;T#MFYDW7YCL?Q?'85SP671R%7R.W"GL0VX7K;=D3?,[L=U MMWWA^G%FZ_/X>6\VH+)C M9UA7HVF1.]8?^H!X0%/*1L?M);2<^7 :4]D(G/0C_BC)ST MMD3VWK][^>+M=YX'9Q>7'\(LY7@P6*_7_?".,LFC5:(D93_@\0 \KXB? M3#_#'UFY,7PB$?$E@=B7"1'PZXI&X7AT-!H-AT>_]'\NIPGB:ST(_82,X?7@ M>#A0@<GQT!#Q+V<]6(LO_&^J^9;AY>O@!09Y') M=-])3Y^+_%1L9B+J3-(CY:C)37%*O'A MX*\/5[?!@L2^I\Z^^FX%>1E)QS+=?\6#]!1:- B5$?HKKPCS]"YO./*.A_V- M#'OO=,'\[/@S$EVI+4@]C 6/2$UA?3BMWLOCD^U2Q9--0EA(QH^2(H=-3F ?]YQ"#@ZONV3+Q4L4B_$SPV=I&7XX:# M7Z)99&Q3DZ2V]'03YGV^/>0U$RH;$T3RE5!X-?G6IG[>I_DZTMEA7)'>%9;X77!+G@6B.(A&U6 M ?(2D-8 5<09X!9;+X/$X2!JD$0F]FL M!*@:H(N@X=M"ZT:.K?O'6"Q\(G.J%\DL^>C'UD2;=B9V"D%:$O"3HFDA#\@U\&6;FZ>8PANB"1N3C*IX1T6QB MRGF=CH?! #X:X5Q25>E8+<6+O>M6C$,P1/\8(S$:1@J S+_YXHR,FPV M#D:!3D>ASA(_$.@^ I6BN/CG^J^*#="5X)IAK6-:LV% _PE>VD%_Y(K^Z-FA M/[)%?]0&^J-OA_YTS5M#'\F&-?JU7A#1GZC-:S'E:_8D\,OISP%[@QT3] ]A M:,@_EFP)>%T&N !="!=V; -UJ-NY0,0\_7GX6MP(?D]9T/"V3I7&Q:.@;=5OB/[NQH= IJN$.02M6ZB:A@1_$<;CA,O&CO^FR^3U.L\)S& 6S M*=,@[$2BC8%!M:4AR"J!*H5YW[(]&W4#8.W%\1U ;5 0OPGPNSE=O0%H:ISO M'W-Z_V]/!PG<]/]YK8S#*7Z?.^_^63;K!J)^*3>Z67#6\'[Y?EY'0%8:X.;C M+F":M9#@3,4A5<>Z;]A.OV5(FS3M!NJ?@B8)81,>QRN6WX^4MK16)'>$;+T5 M7A/D F^-(!+!>078+>%,<8N-EU%NVKT;SK<\H@%-*)M_4"MN0?W(EF539D<@ MUYC@51$N"%>I(?'[( ^%OC.\;;5<)K=1WV[8W@BBYX,H+-(W(?6G8\3UW9W] MPJ%.H2.,+4SQ0Y$N6!]21<);E8%R'<@*05K)&?2V392!?Z(35/0OI5P1X3X M!IWG,0;5!LW#L!>/.!(5VFT-1E:NU?EHR5'ME#2RY;B\(<%*K:>VP]%L2I/( M^A['?EY72YLJ ]Q\W&E98]3"6M3DXJ#4(95W7].TTN_.BJ9!TVZ@3H6O/VI^ MNXUGW'H)_BBI(T3-K7/#01;X*%2LD.GW"5V^+'PQU?\97(XO$>OY@K"@$627(2R$]XVO1AN$A MGZV7\HXKM:5_Y4J^BV:_>$3M^1]02P,$% @ FD'_5O'3J#S*! 3RP M !4 !S<')O+3(P,C,P-S,Q7W!R92YX;6S5FEV3VC84AN\SD_^@NC?M3(WY MV&2SS)(,97#84G;Z4U&V ?05)8\DEC@W_?(H!2#V< F[5A<\"'K/7IU M'EE8LB\_+%-.GD!I)D4G:-3J 0$1RX2):2>8ZY#JF+& :$-%0KD4T E6H(,/ M[U^_NOPA#,G53?^>A&1F3*;;4;18+&K)A DM^=Q@2%V+91J1,'3U>Z-/Y/=U MA*"@&?+Z%<$7YE'HO+03V&QLDK$< M*UZ3:HINZZW(B8)MS7)/M&CEDL;%Q464'RW6UZRL-C;0B/Z\NWV,9Y#2$!D@ MLWBG*723F"_J;7-OHO5!5U^SMLXCW)Z",.ZS*Y)K89A9]<5$JC3O44#RY+9G"B:=0&=*ABZ:]?7C$ -] M/B60665X?FB69AP"$FWU*U,XAH3):]]B04$ 2P,B@<2%L1WXCWO^?DUY,Y1E M7,B$.YESA!KBVE0^10DPVV+3?K%I:N8IPA^?>Q+GC^Y8&T5C4TP%MV-'*E?( MZ1AX)R@11=_34!>[G=BNWW Z/=;0CJAH:!M?5\6%D%3%+AQ^+;#;/P\V-:*, M*HP7QC.<\9QZHF1:FIQ-:[+4J%0)J$Z WC3VL >*\CX._.5OL#H6TP%Q=7$=,.RP MM;S!YN:3$:;Q6%I%374A%7TZ-F^\8S, ](K3?7*%ETFG0MH15Y_6CF&'[:TW MV-9SPQ"FS'94F'N:'DVM7%M=:.5^';-SSYCA$D&J3*H\M8^88>C).4[QJYY, M3D3XE5!5)_H5^P[P.\\ WS .]_-T#.HTFMNZJJ/;]NHX77C&:427_033P"9L MO4Q]";2#0:I.\*#Q#!'!;[@F^;"7$-R+X0G&/=^.Y9F?+ =2&\K_8MGIJXOR")YPW''M*/JS+V/GDZX">@JW MHJ:ZI(H^'1M_-E_L?2T^F$EQXCIO7U==1OM>'2=_-ES^0'\&1$^FZ5QLECGZ M6%@'Q-4E=L"PP^;/-LJCY"QFAHGI'?X9*V:M'<>L3%E=8&5N'2U_-E,&"NR0 M [Q:RN^#V/O1ZF$R.7Y:?"Y"=>D]YWI#\6:ZL+J]RO8^;;/LAU"FJ*8^^CD@LSP_D] MH^+$1X8.A*@NP6=M.Y#_PU;(9;27FELLL _"KH_8-_M8)Y;\ U!+ 0(4 Q0 M ( )I!_U9?]0;CSQ@ /J& . " 0 !D-3$X-C4P M9#AK+FAT;5!+ 0(4 Q0 ( )I!_U;=*.N2A!$ "P8 +E& 5 " 2(N !S M<')O+3(P,C,P-S,Q7VQA8BYX;6Q02P$"% ,4 " ":0?]6\=.H/,H$ !/ M+ %0 @ '0- &UL4$L% 3!@ % 4 0 $ ,TY $! end